B39.5: Histoplasmosis duboisii
B39.5, histoplasmosis duboisii, is listed as a covered diagnosis in 4 Medicare billing and coding articles that apply to 25 HCPCS Level II codes, including J7999 (Compounded drug, not otherwise classified), C9257 (Injection, bevacizumab, 0.25 mg), G0278 (Iliac and/or femoral artery angiography, non-selective…). The articles come from 2 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.
HCPCS Level II codes with B39.5 as a covered diagnosis
| Code | Description | Medicare coverage | DMEPOS fee 2026 (state range) | Articles listing it |
|---|---|---|---|---|
| J7999 | Compounded drug, not otherwise classified | Special coverage instructions apply | — | 1 |
| C9257 | Injection, bevacizumab, 0.25 mg | Special coverage instructions apply | — | 1 |
| G0278 | Iliac and/or femoral artery angiography, non-selective, bilateral or ipsilateral to catheter insertion, performed at the same time as cardiac catheterization and/or coronary angiography, includes positioning or placement of the catheter in the distal aorta or ipsilateral femoral or iliac artery, injection of dye, production of permanent images, and radiologic supervision and interpretation (list separately in addition to primary procedure) | Carrier judgment | — | 1 |
| G0269 | Placement of occlusive device into either a venous or arterial access site, post surgical or interventional procedure (e.g., angioseal plug, vascular plug) | Special coverage instructions apply | — | 1 |
| J2785 | Injection, regadenoson, 0.1 mg | Carrier judgment | — | 1 |
| J0461 | Injection, atropine sulfate, 0.01 mg | Special coverage instructions apply | — | 1 |
| J3490 | Unclassified drugs | Special coverage instructions apply | — | 1 |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | Special coverage instructions apply | — | 1 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | Carrier judgment | — | 1 |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | Special coverage instructions apply | — | 1 |
| J0280 | Injection, aminophyllin, up to 250 mg | Special coverage instructions apply | — | 1 |
| J1245 | Injection, dipyridamole, per 10 mg | Special coverage instructions apply | — | 1 |
| Q9956 | Injection, octafluoropropane microspheres, per ml | Carrier judgment | — | 1 |
| C9399 | Unclassified drugs or biologicals | Special coverage instructions apply | — | 1 |
| A9700 | Supply of injectable contrast material for use in echocardiography, per study | Special coverage instructions apply | — | 1 |
| C8921 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; complete | Special coverage instructions apply | — | 1 |
| C8922 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; follow-up or limited study | Special coverage instructions apply | — | 1 |
| C8923 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, without spectral or color doppler echocardiography | Special coverage instructions apply | — | 1 |
| C8924 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, follow-up or limited study | Special coverage instructions apply | — | 1 |
| C8928 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report | Special coverage instructions apply | — | 1 |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | Special coverage instructions apply | — | 1 |
| C8930 | Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision | Special coverage instructions apply | — | 1 |
| Q9955 | Injection, perflexane lipid microspheres, per ml | Carrier judgment | — | 1 |
| A9585 | Injection, gadobutrol, 0.1 ml | Carrier judgment | — | 1 |
| Q9953 | Injection, iron-based magnetic resonance contrast agent, per ml | Special coverage instructions apply | — | 1 |
Medicare policy articles listing B39.5
- A53008: Billing and Coding: Intraocular Bevacizumab (Noridian Healthcare Solutions, LLC (MAC - Part A, MAC - Part B); 2 Level II codes)
- A56500: Billing and Coding: Cardiac Catheterization and Coronary Angiography (CGS Administrators, LLC (MAC - Part A, MAC - Part B); 2 Level II codes). LCD with the same title: L33557, L33959
- A57306: Billing and Coding: Transthoracic Echocardiography (TTE) (CGS Administrators, LLC (MAC - Part A, MAC - Part B); 19 Level II codes). LCD with the same title: L33577, L34338
- A57206: Billing and Coding: Lumbar MRI (Noridian Healthcare Solutions, LLC (MAC - Part A, MAC - Part B); 2 Level II codes). LCD with the same title: L34220
A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.
Other B39 diagnoses (Histoplasmosis)
- B39.0 — Acute pulmonary histoplasmosis capsulati
- B39.1 — Chronic pulmonary histoplasmosis capsulati
- B39.4 — Histoplasmosis capsulati, unspecified
Frequently asked questions
Does Medicare cover B39.5 (Histoplasmosis duboisii)?
Medicare covers items and services, not diagnoses. 4 Medicare billing and coding articles list B39.5 as a covered diagnosis for 25 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.
Which HCPCS codes can be billed with ICD-10 B39.5?
The Level II codes from the policies most specific to this diagnosis are J7999 (Compounded drug, not otherwise classified, 1 article); C9257 (Injection, bevacizumab, 0.25 mg, 1 article); G0278 (Iliac and/or femoral artery angiography, non-selective…, 1 article); G0269 (Placement of occlusive device into either a venous or…, 1 article); J2785 (Injection, regadenoson, 0.1 mg, 1 article). Code choice depends on the item supplied; check each code's descriptor.
Which Medicare policy articles list B39.5?
A53008 (Billing and Coding: Intraocular Bevacizumab); A56500 (Billing and Coding: Cardiac Catheterization and Coronary Angiography); A57306 (Billing and Coding: Transthoracic Echocardiography (TTE)), and 1 more article.
What is ICD-10-CM code B39.5?
B39.5 is the ICD-10-CM code for histoplasmosis duboisii, in category B39 (Histoplasmosis), chapter 1: Certain infectious and parasitic diseases.
Next steps
- Run a reimbursement report for a device billed under J7999
- Watch J7999 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J7999
Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.
Chapter 1: Certain infectious and parasitic diseases · All diagnoses · HCPCS lookup